Loading
Imunon, Inc. is a clinical-stage biotechnology company dedicated to the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. The company's pipeline features GEN-1, a DNA-based immunotherapy specifically designed for the localized treatment of ovarian cancer, and ThermoDox, a proprietary heat-activated liposomal formulation of doxorubicin, currently in development for various cancer indications. Additionally, Imunon possesses two feasibility-stage platform technologies aimed at creating nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Established in 1982 and based in Lawrenceville, New Jersey, the firm was known as Celsion Corporation before rebranding to Imunon, Inc. in September 2022.
Previous close
$1.47
+$0.02 · +1.38%
Regular session · ET · Market data may be delayed.
Imunon, Inc. is a clinical-stage biotechnology company dedicated to the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. The company's pipeline features GEN-1, a DNA-based immunotherapy specifically designed for the localized treatment of ovarian cancer, and ThermoDox, a proprietary heat-activated liposomal formulation of doxorubicin, currently in development for various cancer indications. Additionally, Imunon possesses two feasibility-stage platform technologies aimed at creating nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Established in 1982 and based in Lawrenceville, New Jersey, the firm was known as Celsion Corporation before rebranding to Imunon, Inc. in September 2022.
Day range
Current $1.47
52-week range
Current $1.47
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
44
Fair Value
Sentiment
58
Mixed
Risk
72
High Risk
Momentum
21
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Imunon, Inc. is a clinical-stage biotechnology company dedicated to the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. The company's pipeline features GEN-1, a DNA-based immunotherapy specifically designed for the localized treatment of ovarian cancer, and ThermoDox, a proprietary heat-activated liposomal formulation of doxorubicin, currently in development for various cancer indications. Additionally, Imunon possesses two feasibility-stage platform technologies aimed at creating nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Established in 1982 and based in Lawrenceville, New Jersey, the firm was known as Celsion Corporation before rebranding to Imunon, Inc. in September 2022.
Day range
Current $1.47
52-week range
Current $1.47
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | 500K USD | 500K USD |
| Gross profit | — | — | — | 500K USD | 500K USD |
| Research and development | 7.78M USD | 11.64M USD | 11.29M USD | 11.73M USD | 10.62M USD |
| Selling, general, and administrative | 6.87M USD | 7.49M USD | 9.74M USD | 13.69M USD | 10.89M USD |
| Operating expenses | 14.65M USD | 19.13M USD | 21.03M USD | 25.42M USD | 21.51M USD |
| Interest income | 155.67K USD | 450.22K USD | 725.82K USD | 502.58K USD | 18.15K USD |
| Interest expense | — | — | 197.08K USD | 5.03M USD | 569.88K USD |
| Depreciation and amortization | 698.9K USD | 718.12K USD | 720.01K USD | 731.63K USD | 702.92K USD |
| Operating income | −14.65M USD | −19.13M USD | −21.03M USD | −24.92M USD | −21.01M USD |
| Net income | −14.5M USD | −18.62M USD | −19.51M USD | −35.9M USD | −20.77M USD |
Company facts updated Sep 13, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$10.00
580.27% upsideLimited analyst sample: 4 ratings. Interpret the distribution with caution.
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
